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Background: Patient-reported outcome validation needs to achieve validity and reliability standards. Among
reliability analysis parameters, test-retest reliability is an important psychometric property. Retested patients must be
in a clinically stable condition. This is particularly problematic in palliative care (PC) settings because advanced
cancer patients are prone to a faster rate of clinical deterioration. The aim of this study was to evaluate the methods
by which multi-symptom and health-related qualities of life (HRQoL) based on patient-reported outcomes (PROs)
have been validated in oncological PC settings with regards to test-retest reliability.
Methods: A systematic search of PubMed (1966 to June 2013), EMBASE (1980 to June 2013), PsychInfo (1806 to
June 2013), CINAHL (1980 to June 2013), and SCIELO (1998 to June 2013), and specific PRO databases was
performed. Studies were included if they described a set of validation studies. Studies were included if they
described a set of validation studies for an instrument developed to measure multi-symptom or multidimensional
HRQoL in advanced cancer patients under PC. The COSMIN checklist was used to rate the methodological quality
of the study designs.
Results: We identified 89 validation studies from 746 potentially relevant articles. From those 89 articles, 31
measured test-retest reliability and were included in this review. Upon critical analysis of the overall quality of the
criteria used to determine the test-retest reliability, 6 (19.4%), 17 (54.8%), and 8 (25.8%) of these articles were rated
as good, fair, or poor, respectively, and no article was classified as excellent. Multi-symptom instruments were
retested over a shortened interval when compared to the HRQoL instruments (median values 24 hours and 168
hours, respectively; p = 0.001). Validation studies that included objective confirmation of clinical stability in their
design yielded better results for the test-retest analysis with regard to both pain and global HRQoL scores (p < 0.05).
The quality of the statistical analysis and its description were of great concern.
Conclusion: Test-retest reliability has been infrequently and poorly evaluated. The confirmation of clinical stability
was an important factor in our analysis, and we suggest that special attention be focused on clinical stability when
designing a PRO validation study that includes advanced cancer patients under PC.
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Advanced cancer patients under palliative care (PC) ex-
perience many physical, psychosocial, and existential
problems [1]. The PC team is essential for the screening,
diagnosis, and treatment of cancer symptoms with the
aim of improving the patients’ health-related quality of
life (HRQoL). Therefore, an ideal assessment of symp-
toms and HRQoL should be performed using validated
patient-reported outcome (PRO) instruments [2].
The process of PRO validation requires time and in-
cludes rigorous methods of data analysis. It encompasses
the translation of foreign languages, cultural adaptation,
and the evaluation of psychometric properties. Overall, a
PRO validation needs to achieve the standards of validity
and reliability [2]. Among reliability analyses, the most
important are internal consistency, inter-rater reliability,
and test-retest reliability. Test-retest reliability can be
defined as “a measure of the reproducibility of the scale,
that is, the ability to provide consistent scores over time
in a stable population” [3].
Retested patients must be in a stable condition with
respect to the construct to be measured by the PRO.
This situation is particularly problematic in PC settings
because advanced cancer patients are prone to a faster
rate of clinical deterioration [4].
Thus, the aim of the present study was to evaluate the
method by which multi-symptom and HRQoL PROs




A systematic literature review was used.
Eligibility criteria
The studies included in this systematic review met all of
the following criteria: (1) validation study of a multidimen-
sional quality of life instrument or a multidimensional
symptom assessment instrument; (2) publication in a
peer-reviewed journal; and (3) analysis of a population
composed mainly of advanced cancer patients undergoing
PC (or hospice care, end-of-life care, or some similar type
of care).
Studies were excluded for any of the following reasons:
(1) the study was not published as a full article (i.e., con-
ference proceedings were excluded); (2) the study con-
tained pediatric data; or (3) the publication was a
duplicate publication.
Data sources
Validation studies of PROs were retrieved from the fol-
lowing online databases: PubMed (1966 to June 2013),
EMBASE (1980 to June 2013), PsychInfo (1806 to
June 2013), CINAHL (1980 to June 2013), and SCIELO(1998 to June 2013). The Patient-Reported Outcome
and Quality of Life Instrument Database (PROQOLID)
[5] (http://www.proqolid.org/) and the Australian Centre
on Quality of Life (ACQOL) [6] (http://www.deakin.edu.
au/research/acqol/index.php) were also used to search for
validation studies.
Search strategy
Our search strategies for PubMed included the follow-
ing: (1) quality of life instruments: (instrument OR ques-
tionnaire OR scale OR inventory OR checklist) AND
(reliability OR test-retest OR validation OR psychomet-
ric* OR retest OR repeatability) AND (cancer OR tumor
OR tumour OR carcinoma OR malignancy OR “neo-
plasms” [MESH]) AND “quality of life” AND (palliative
care OR end-of-life OR “end of life” OR hospice OR
terminal OR advanced); (2) multiple-symptom instru-
ments: (instrument OR questionnaire OR scale OR in-
ventory OR checklist) AND (reliability OR test-retest
OR validation OR psychometric* OR retest OR repeat-
ability) AND (cancer OR tumor OR tumour OR carcin-
oma OR malignancy OR “neoplasms” [MESH]) AND
(symptom OR symptoms) AND (palliative care OR end-
of-life OR “end of life” OR hospice OR terminal OR ad-
vanced). Searches using EMBASE, PsychInfo, CINAHL,
and SCIELO were conducted by combining each of the
terms used in the PubMed search strategy. With regards
to the PROQOLID and ACQOL databases, references
were individually screened. To identify additional papers,
the reference lists of relevant articles were reviewed by
one of the authors (CEP).
Data extraction
Initial searches (titles and abstracts) were conducted in-
dependently by CPS and FT. The studies with full text
available were further reviewed, the data were independ-
ently extracted by two other reviewers (CEP, CPS), and
the data were verified by a third reviewer (BSRP).
A standardized data collection form was used. The
data collected included study demographics (year of
publication, country in which the study was conducted,
language in which the instrument was administered), the
name of the instrument, and information about the
characteristics of the patients enrolled (age, performance
status). We also collected data regarding the statistical
methods employed to perform the test-retest analysis,
the time frame from test to retest, the total number
of patients included in the study, and the number of
patients included in the reliability test-retest analysis.
If the sample size for the test-retest reliability was
planned a priori, the study was included only if the
article stated that the patient was clinically stable. The
following QoL domains were systematically extracted
from each article: global, physical, psychological, social,
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symptoms, we specifically analyzed the pain, fatigue,
nausea, anxiety, and depression domains.
Analytic approach
The COSMIN (COnsensus-based Standards for selection
of health Measurement INstruments) checklist [7] was
used to rate the methodological quality of the study de-
signs. Because our focus was test-retest reliability, only
the COSMIN Box B (reliability) was used. The “worst
score counts” algorithm was used for the analysis [8].
Briefly, each item from COSMIN Box B was rated indi-
vidually as “excellent”, “good”, “fair”, or “poor”, and an
overall score was given by taking the lowest score of any
of the items.
Because different statistical methods were used in
many of the studies, a robust meta-analysis of the data
was not possible. Therefore, to perform a pooled ana-
lysis, we followed the method of Terwee et al. [9] and
accepted a minimum reliability threshold of 0.70 as a
measure of “adequate test-retest results”. Each extracted
domain was classified as the number of articles with
test-retest values ≥ 0.70. The number of adequate test-
retest results was associated with the evaluated outcome
(HRQoL versus symptoms) and with the evidence pro-
vided for clinical stability, as measured by item 7 of
COSMIN Box B. For this analysis, a chi-square test for
linear trend was used. In addition, the time (in hours) to
retest was compared between groups with adequate and
non-adequate test-retest results using the Mann–Whit-
ney U Test. Data are presented as median values and
percentiles of 25 (P25) and 75 (P75).
The PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines for building re-
views were followed during the preparation of this review
(see the PRISMA checklist in the Supplementary file).
Results
Figure 1 summarizes the identification and selection of
studies. We identified 89 articles describing validation
studies of PRO that evaluated advanced cancer patients
under PC. Of those, 31 (34.8%) measured test-retest reli-
ability. Information from the included studies is detailed
in Table 1.
Methodological quality of the studies
Two authors (CEP, EMB) classified the articles according
to the COSMIN guidelines; the percentage of agreement
between coders was 85.3% (Cohen’s Kappa coefficient =
0.764). Any disagreements in interpretation were resolved
by a discussion with a third author (BSRP). There were 4
(12.9%) [11,25,28,40], 17 (54.8%) [10,12-15,18,20,24,26,27,
30-32,34,36-38], and 10 (32.2%) [16,17,19,21-23,29,33,35,39]
articles classified as good, fair, and poor, respectively, withregards to the overall quality criteria. No article was classi-
fied as excellent according to the aforementioned criteria.
The global quality classification per item is described
in Figure 2.
Sample sizes
A total of 29 studies (29 of 31; 93.5%) [10-19,21-23,25-40]
described the number of patients submitted to the test-
retest analysis. Of those, the median (P25-P75) number of
patients included was 60 (32–119). The majority of the
studies (24 of 29; 82.8%) [10-12,14-16,18,19,21-23,25-29,
31,32,34-36,38-40] included fewer than the total number
of patients for the reliability analysis. Overall, 53.8% (95%
CI 19.6%-87.9%) of the total number of analyzed patients
were used for the test-retest reliability analysis. Only 2 ar-
ticles [28,37] described the sample size calculation for the
test-retest analysis. One study [35] used a reference from
others recommending that at least 50 patients should be
used for this type of statistical analysis.
Time to retest
The time interval to retest was clearly stated in all of the
included studies [10-40]. The median (P25-P75) time
was 72 (27–168) hours. The median (P25-P75) time in-
tervals for the retest were 24 (3.25-60) hours and 168
(48–204) hours for the symptom and HRQoL validation
studies, respectively (p = 0.001).
Confirmation of clinical stability
Of the 31 analyzed articles, 10 (10 of 31, 32.3%)
[11-15,20,21,26,36,38] clearly stated that only clinically
stable patients were submitted to the retest. The confirm-
ation of clinical stability in accordance with the COSMIN
checklist was associated with adequate results for the test-
retest analysis regarding both pain and global HRQoL
scores (p < 0.05, Table 2). Of those studies, 6 used 1 or
more of the following objective criteria to define a stable
condition: patient perception of change (n = 2) [11,20];
stable doses of opiates (n = 1) [36] or lack of a new medi-
cation for symptom treatment (n = 2) [14,38]; emergency
department visit and/or hospitalization (n = 1) [14]; and
change in Performance Status or in daily living activities
(n = 1) [12].
Scores of retest
In the present review, we chose to perform statistical com-
parisons only for the pain and global HRQoL scores be-
cause they were the most commonly described domains
in the selected studies (Table 3). Taking into consideration
a set value of ≥ 0.70 as an adequate result in the test-retest
analysis, 50% (9 of 18, 50%) [13,20,25,29,32,35-38] and
45% (9 of 20, 45%) [10-12,18,23-25,32,40] of the studies
with pain and global HRQoL values, respectively, were
considered adequate.
Figure 1 PRISMA flow diagram for search strategy.
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time intervals for the retest in the studies with adequate
results for the retest statistical analysis (value ≥ 0.70) in
comparison with those with non-satisfactory results
(value <0.70) (Table 4).
Three studies [18,29,40] compared 2 different time
frame intervals for the retest. Two of them [18,40] mea-
sured global HRQoL 3 hours and 7 days after the first
evaluation; the test-retest results were 0.84-0.93 and 0.63
at 3 hours and 7 days, respectively. The other validation
study [29] evaluated cancer symptoms using the Edmon-
ton Symptom Assessment System (ESAS) scale. That
study found higher test-retest values for shorter time in-
tervals, with the exception of the symptom of fatigue
(Table 5).
Statistical methods used
Of those instruments with continuous scores (n = 29), 11
(11 of 29, 37.9%) [11,12,14,18,20,23,25,28,31,38,40] eval-
uated the test-retest reliability using the intraclass cor-
relation coefficient, and 14 (14 of 29, 48.3%) [10,13,15,
17,24,27,29,30,32,34-37,39] performed some type of cor-
relation analysis such as Spearman’s (n = 6) or Pearson’s
(n = 8) test. Interestingly, for those studies in which the
intraclass correlation coefficient (ICC) method was used,
none described the statistical model or formula used;
therefore, no study could be classified as “excellent”according to item 11 in Box B of the COSMIN guide-
lines. Two studies used paired analysis (repeated mea-
sures of analysis of variance [ANOVA], n = 1; paired
t test, n = 1) to evaluate test-retest reliability [16,33].
Three studies with ordinal score instruments calculated
the weighted kappa statistic [20,21,26]. Two studies did
not describe the type of statistics used [19,22].
Discussion
In this study, we investigated the methods by which val-
idation studies of PRO have been performed in the PC
setting, particularly with regards to test-retest reliability.
In general, the methodological quality of this psychomet-
ric property was investigated poorly to fairly; according
to the COSMIN checklist, only 12.3% of the studies were
considered of good quality, and none were considered of
excellent quality. In addition, we highlighted the import-
ance of verifying the clinical stability of advanced cancer
patients before performing the retest. Based on our re-
sults, clinical stability is even more important for test-
retest reliability than the accurate definition of the time
interval at which the retest is performed.
In our review, we identified 89 validation studies that
included cancer symptoms and/or HRQoL as outcome
variables. Of those, only 31 (34.8%) evaluated the test-
retest reliability. As the test-retest reliability is an essen-
tial psychometric property to be measured in validation


















AQEL 22 ACP. Median age = 67.5 years,
mean and median KPS = 62.3
and 70, respectively.
71 30 3 days Not described Spearman Rank correlation
Cohen
et al. [11]
Canada (English) MQOL 16 ACP. Could be receiving
chemotherapy. Mean age:
59 years). Life expectancy
greater than 2 weeks.
100 49-59 2 days Yes ICC
Llobera
et al. [12]
Spain (Spanish) HRCA-QL index 5 APC (end-of-life). Median
survival = 59 days.





Greece (Hellenic) PLQI 28 Patients with symptomatic
incurable cancer. Off anticancer
treatment for≥ 3 months. All
patients classified as ECOG-PS≥ 2
(ECOG-PS3 = 68%).
120 120 7 days No Spearman Rank correlation
Steinhauser
et al. [14]
USA (English) QUAL-E 25 Terminal CHF, ESRD, COPD, and
stage IV cancer (56%).





POS 10 ACP (life expectancy < 1 year),
non-terminal, many of them
undergoing chemotherapy.
109 30 7 days No Pearson correlation
Suárez-del-Real
et al. [16]
Mexico (Spanish) QLQ-C15-PAL 15 ACP undergoing exclusive palliative
care. KPS < =70% = 78%.






Poland (Polish) QLQ-C15-PAL 15 ACP undergoing palliative care. 129 129 7 days No Spearman Rank correlation
Kim et al. [18] Korea (Korean) MQLS 32 Mortality rate during study = 80%,
ECOG-PS > = 3 = 71.2%.
70 54-64 3 hours and
7 days
No ICC
Kim et al. [19] Korea (Korean) HQLS 43 Advanced cancer patients under
exclusive palliative care.
ECOG-PS3/4 = 64.2%.
180 88 1-2 weeks No Not described
Serra-Prat
et al. [20]









POS 10 ACP under palliative care. ECOG-PS
3/4 = 58%.
65 24 2 days No Weighted kappa
agreement
Guo et al. [22] USA (English) Brief Hospice Inventory 17 Geriatric population (mean age =
78 years, 83% ≥ 70 years) 47% Advanced
cancer under hospice care in 47%.
145 63 1 week No Not described
Lo et al. [23] China (Chinese) MQOL 16 Incurable ACP. 462 20 2 days No ICC
Shahidi et al. [24] Iran (Persian) MQOL 16 Mean KPS = 74.8%. Any type of
incurable cancer with an estimated
life expectancy of < 12 months was
considered for the study.
61 Not clearly
stated




















Table 1 Instruments developed to assess symptoms or quality of life of cancer patients under palliative care (Continued)





10 Hospice patients, including ACP.
Limited self-care and completely
disabled = 41.7%.
682 307 21.2 hours
(mean)
No ICC
Hearn et al. [26] England and
Scotland (English)
POS 10 ACP (98%) under palliative care.
Limited activity or disabled = 47.1%.
168 34 3-7 days Yes Weighted kappa
agreement
Wilson et al. [27] Canada (English) SISC 13 ACP under palliative care. Median
survival = 46 days.
68 46 1-3 days No Pearson correlation
Agra et al. [28] Spain (Spanish) RSCL 39 ACP under palliative care. Terminal
illness (life expectancy < 6 months).
KPS < 70% in 65.2%.
118 116 24 hours No ICC
Chang et al. [29] USA (English) ESAS 10 ACP under palliative care. Mostly
elderly male patients.
233 19-23 1 day and 1
week
No Spearman Rank correlation
Stiel et al. [30] Germany
(German)
MIDOS 12 ACP under palliative care. ECOG-PS
3/4 = 56.6%.
60 60 1 day No Pearson correlation
Moro et al. [31] Italy (Italian) ESAS 10 ACP under exclusive palliative care.
In-patients, KPS≤ 40 = 75%.
Median survival = 35 days.
241 60 24-48 hours No ICC
Mystakidou
et al. [32]
Greece (Greek) MDASI 19 ACP under palliative care. ECOG-PS
3/4 = 63%.
150 100 3 days No Pearson correlation
Pautex et al. [33] Swiss (French) ESAS 10 ACP under palliative care. Mean
age = 72 years.
42 42 1 day No Paired t test
Stiel et al. [34] Germany
(German)
HOPE-SP-CL 16 ACP under palliative care; inpatients. 31,055 332-472 7 days No Spearman Rank correlation
Carvajal et al. [35] Spain (Spanish) ESAS 10 ACP under palliative care.
KPS ≤ 70% = 45.5%.
171 146 0-6 hours No Spearman Rank correlation





MIDOS 12 ACP under palliative care. ECOG-PS
3/4 = 81.2%.
128 76 1-6 days Yes Pearson correlation
Kwon et al. [37] Korea (Korean) ESAS 10 Mostly symptomatic ACP undergoing
active antineoplastic treatment.
162 162 2-4 hours No Pearson correlation
Aoun et al. [38] Australia (English) SAS 7 ACP under palliative care. 572 60 2 hours Yes ICC
Pereira et al. [39] Portugal
(Portuguese)
FACT-G 28 ACP under PC (end-of-life). Inpatients
and outpatients. Performance status
not described.
346 27 8-9 days No Pearson correlation
Sterkenburg
et al. [40]
Canada (English) MQLS 32 Most were ACP under palliative care.
Mean survival = 49.56 days.
84 73 3 hours and
7 days
No ICC
USA United States of America, ICC intraclass correlation coefficient, CHF chronic heart failure, ANOVA Analysis of variance, ESRD end stage renal disease, COPD chronic obstructive pulmonary disease, AQEL Assessment
of Quality of Life at the End of Life, MQOL McGill Quality of Life Questionnaire, HRCA-QL index Hebrew Rehabilitation Centre for Aged Quality of Life Index, PLQI The Palliative Care Quality of Life Instrument, QUAL-E
Quality of Life at the End of Life, POS Palliative Care Outcome Scale, QLQ-C15-PAL The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL, MQLS McMaster Quality of Life Scale, HQLS
Hospice Quality of Life Scale, SISC Structured Interview for Symptoms and Concerns, RSCL Rotterdam Symptom Check List, ESAS Edmonton Symptom Assessment System, MIDOS Minimal Documentation System, MDASI
MD Anderson Symptom Inventory, HOPE-SP-CL Multidimensional symptom and problem checklist, SAS Symptom Assessment Scale, FACT-G Functional Assessment of Cancer Therapy- General. 1 IsiZulu (49.6%), English




















Figure 2 Quality criteria of the included studies according to the COSMIN checklist.
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atically measuring it because of the instability of ad-
vanced cancer patients. Overall, half of the evaluated
test-retest reliability scores were classified as inadequate
when 0.70 was used as the threshold value [9]. The pres-
sure experienced by scientific researchers to publish
positive results [41] may also explain why only 34.8% of
validation studies measured the test-retest reliability.
Furthermore, it is possible that inappropriate test-retest
values were omitted from some publications.
It is essential to accurately estimate the sample size
prior to beginning a study. An insufficient sample size
might not detect true differences, which might lead to
unreliable results. Conversely, an excessive sample size
may produce unnecessary financial losses and ethical
concerns regarding futile exposure of study participants
[42]. With regards to test-retest reliability analysis, we
observed that determining an adequate sample size is
not a common practice because only 2 studies [28,37]
described performing a sample size calculation prior toTable 2 Association between the test-retest reliability
values and the evidence of clinical stability
Test-retest values Were patients stable in
the interim period on the
construct to be measured?
P*
Poor Fair Good Excellent
N (%) N (%) N (%) N (%)
Global HRQoL scores 0.015
< 0.70 2 (18.2) 5 (45.5) 4 (36.4) 0 (0)
≥ 0.70 0 (0) 1 (12.5) 5 (62.5) 2 (25.0)
Pain scores 0.031
< 0.70 2 (18.2) 3 (27.3) 3 (27.3) 1 (9.1)
≥ 0.70 0 (0) 1 (11.1) 4 (44.4) 4 (44.4)
HRQoL health-related quality of life.
*p-value for linear trend.the study. Overall, the median number of included pa-
tients for test-retest analysis was 60, which represents
53.8% of the total number of included patients. One
study [35] justified the sample size by citing a rule of
thumb suggesting that 50 patients would be sufficient
for the analysis [43,44].
A basic concept regarding test-retest reliability is the
need to retest clinically stable patients [45]. The retest
of advanced cancer patients is challenging because they
are in a dynamic phase of their disease in which symp-
toms and functionality are prone to decline quickly.
The retest of a clinically unstable patient may incor-
rectly define a PRO as a non-reliable tool. Our results
confirm the importance of verifying the clinical stability
of the patients before retesting. In addition, our reviewn (%) n (%)
Global HRQoL 19 11 (57.9) 8 (42.1)
Emotional 8 1 (12.5) 7 (87.5)
Physical 5 1 (20) 4 (80)
Social 6 2 (33.3) 4 (66.7)
Functioning 3 0 (0) 3 (100)
Existential 6 1 (16.7) 5 (83.3)
Global symptoms 5 2 (40) 3 (60)
Pain 18 9 (50) 9 (50)
Nausea 12 5 (41.6) 7 (58.3)
Fatigue 11 6 (54.5) 5 (45.5)
Anxiety 10 6 (60) 4 (40)
Depression 9 4 (44.4) 5 (55.6)
HRQoL health-related quality of life.
Table 4 Median values of time intervals of studies with













Global HRQoL 19 168 (36–168) 60 (36.75-206) 0.565
Emotional 8 1681 168 (48–204) -
Physical 5 1681 108 (30–195) -
Social 6 1862 108 (48–195) -
Functioning 3 - 1683 -
Existential 6 1201 168 (48–232) -
Global symptoms 5 25.752 483 -
Pain 18 120 (42–168) 48 (3–168) 0.262
Nausea 12 108 (33–168) 24 (3–72) 0.146
Fatigue 11 48 (24–168) 3 (2.5-120) 0.184
Anxiety 10 72 (36–168) 48 (8.25-144) 0.443
Depression 9 102 (27–168) 60 (18.75-96) 0.587
HRQoL health-related quality of life.
*Mann–Whitney test.
1Only one study. 2Only two studies. 3Only three studies.
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define a stable condition.
The definition of an adequate between-assessment
time gap for the retest is of the utmost importance. An
insufficient time period might allow respondents to re-
call their first answers, and a longer interval might allow
for a true change of the construct to occur [2,45]. The
appropriate time interval depends on the construct to
be measured and the target population [46]; however,
approximately 2 weeks is often considered generally
appropriate [47]. Nevertheless, the time interval over
which to retest advanced cancer patients under PC is
still a matter of debate. Some authors have considered
retesting advanced cancer patients at least 3 days apart
as a measure of responsiveness but not as a measure of
test-retest reliability [4].
In fact, because of concerns about reassessing an unstable
patient, some authors (n = 7) reapplied the questionnairesTable 5 Test-retest reliability scores measured at two differen
Author (year) Time to
retest Global HRQoL Pain
Kim et al. [18] 3 hours 0.93 NA
7 days 0.63 NA
Chang et al. [29] 24 hours NA 0.79
7 days NA 0.75
Sterkenburg et al. [40] 3 hours 0.84 NA
7 days 0.63 NA
NA not evaluated.at very short intervals (i.e., less than 24 hours). Jim et al.
[48] investigated daily and intraday changes in the fatigue,
depression, sleep, and activity scores in a cohort of cancer
patients undergoing chemotherapy. Significant changes
were observed over time. Additionally, Dimsdale et al. [49]
investigated cancer-related fatigue every hour for 72 con-
secutive hours and observed a diurnal variation in fatigue.
HRQoL, on the other hand, is a multidimensional construct
that encompass physical, psychological, social, and spiritual
domains. In general, instruments that measure HRQoL use
recall periods of 7 days. Although HRQoL is not commonly
assessed on a daily basis, it is expected to behave stably over
a few days, especially the social, existential, and global do-
mains. Consequently, we observed that multi-symptom in-
struments are generally retested within a shorter time
frame than HRQoL instruments.
There was a trend of shorter time periods in the ad-
equate test-retest reliability results when compared with
the scores with inadequate results (less than 0.7). One
reason contributing to the non-significant results might
be the large interquartile range for some of the domains;
since few studies were analyzed, there was insufficient
statistical power for further conclusions. Three studies
[18,29,40] evaluated the retest reliability at 2 different
time points (< 24 hours and 1 week after the first evalu-
ation); in general, a lower time interval was associated
with a better retest analysis result. Considering the me-
dian time interval used in the studies with adequate test-
retest results, in addition to the findings from studies
that used two different time intervals for the retest, we
can recommend that patients under palliative care for
advanced cancer should be retested somewhere around
24 to 48 hours later when evaluating cancer symptoms
and 2 to 7 days later when assessing HRQoL. However,
we believe that the most important factor is not the time
itself but rather confirmation of clinical stability before
retesting patients.
As mentioned previously, we concluded that the test-
retest reliability analysis was of low quality according to
the COSMIN checklist. Other studies using the same
guidelines but not the same population have yielded
similar results [50-52]. The most troublesome questiont time intervals from the first evaluation
Scores
Nausea Fatigue Anxiety Depression
NA NA NA NA
NA NA NA NA
0.58 0.39 0.62 0.81
0.31 0.65 0.35 0.54
NA NA NA NA
NA NA NA NA
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an intraclass correlation coefficient calculated?”), with
62% of studies classified as poor to fair quality. The pre-
ferred test-retest reliability statistic depends on the type
of response options. In our review, the majority of the
studies evaluated continuous scores. In these cases, the
ICC [31] is the preferred statistic [46,47,53]. Moreover,
the use of correlation coefficients (Pearson’s and Spear-
man’s tests) is not adequate because they do not include
a consideration of systematic error [46]. In the present
study, 18 of 29 studies evaluating continuous scores used
a correlation analysis, but they did not evaluate the
agreement by using the ICC. Six different versions of
ICC can be used depending on various assumptions, and
4 of those are subdivided into consistency or absolute
agreement, yielding a total of 10 different ICC calcula-
tions [54]. The choice of the correct index has a highly
significant impact on the numerical value of the ICC
[53]. Even in those studies that correctly used the ICC,
none stated the version of the ICC used.
This study has some limitations. Because the studies
evaluated test-retest reliability using different statistics, we
could not perform a robust meta-analysis. Therefore, we
decided to use 0.7 as the threshold for adequate results on
test-retest reliability to perform a pooled data analysis.
However, the categorization of the test-retest results as a
function of a predefined cut-off point may be considered
an inadequate simplification. Another limitation is that we
did not include in the systematic review other instruments
developed to assess only one symptom (fatigue or pain
scales, for example). In addition, we did not include ab-
stracts from meetings because it would be difficult to ex-
tract the necessary data.Conclusions
In conclusion, we determined that test-retest reliability
has been infrequently and poorly evaluated in valid-
ation studies of PRO assessing advanced cancer patients
under PC. Multi-symptom instruments were retested
over a shorter time interval when compared to HRQoL.
The confirmation of clinical stability was an important
factor in our analysis, and we suggest that special atten-
tion to this parameter is required when designing a
PRO validation study that includes advanced cancer pa-
tients under PC.
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